Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
Yunyun XiongBruce C V CampbellLee H SchwammXia MengAoming JinMark W ParsonsMarc FisherYong JiangFengyuan CheLihua WangLi ZhouHongguo DaiXintong LiuYuesong PanChunmiao DuanYuming XuLiangxue LaiLixia ZongZefeng TanWanxing YeHao WangZiran WangManjun HaoZhixin CaoLiyuan WangShuangzhe WuHao LiZixiao LiXingquan ZhaoYong-Jun Wangnull nullPublished in: The New England journal of medicine (2024)
In this trial involving Chinese patients with ischemic stroke due to large-vessel occlusion, most of whom did not undergo endovascular thrombectomy, treatment with tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability and similar survival as compared with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage appeared to be higher. (Funded by the National Natural Science Foundation of China and others; TRACE-III ClinicalTrials.gov number, NCT05141305.).